Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, Le Garff G, Falchero L, Huchot E, Vieillot S, Corre R, Kazulinski L, Bizieux A, Bigay-Gamé L, Morel H, Molinier O, Chouaïd C, Guisier F. Dhamelincourt E, et al. Among authors: rousseau bussac g. Target Oncol. 2023 Nov;18(6):905-914. doi: 10.1007/s11523-023-01014-z. Epub 2023 Nov 15. Target Oncol. 2023. PMID: 37966566
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, Do P, Schott R, Dansin É, Arrondeau J, Auliac JB, Geier M, Chouaïd C. Descourt R, et al. Among authors: rousseau bussac g. Cancers (Basel). 2022 Mar 30;14(7):1751. doi: 10.3390/cancers14071751. Cancers (Basel). 2022. PMID: 35406523 Free PMC article.
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C. Descourt R, et al. Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14. Lung Cancer. 2019. PMID: 31491676 Free article.
[Supportive cares on thoracic oncology].
Rousseau-Bussac G, Crequit P, Masanes MJ, Chouaïd C. Rousseau-Bussac G, et al. Bull Cancer. 2012 Nov;99(11):1057-64. doi: 10.1684/bdc.2012.1650. Bull Cancer. 2012. PMID: 23073345 Review. French.
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
Akli A, Girard N, Fallet V, Rousseau-Bussac G, Gounant V, Friard S, Trédaniel J, Dujon C, Wislez M, Duchemann B, Giroux-Leprieur E. Akli A, et al. Among authors: rousseau bussac g. Target Oncol. 2022 Nov;17(6):675-682. doi: 10.1007/s11523-022-00915-9. Epub 2022 Sep 21. Target Oncol. 2022. PMID: 36129569
[Management of malignant pericardial effusion in lung cancer].
Rousseau-Bussac G, Crequit P, Alifano M, Chouaid C. Rousseau-Bussac G, et al. Rev Mal Respir. 2014 Oct;31(8):746-53. doi: 10.1016/j.rmr.2014.02.011. Epub 2014 Apr 24. Rev Mal Respir. 2014. PMID: 25391509 Review. French.
21 results